1 min read
Apimeds Pharmaceuticals US, Inc. Posts $2.89 Million Revenue and $7.68 Diluted GAAP EPS
Third-quarter basic GAAP EPS was $19.13.
Apimeds Pharmaceuticals US, Inc. recorded $2.89 million in third-quarter revenue, with basic GAAP EPS of $19.13 and diluted GAAP EPS of $7.68.